BRPI0417476A - derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer - Google Patents
derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimerInfo
- Publication number
- BRPI0417476A BRPI0417476A BRPI0417476-3A BRPI0417476A BRPI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A BR PI0417476 A BRPI0417476 A BR PI0417476A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treatment
- alzheimer
- tricyclically
- indole
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- RUCHEPWOSATICL-UHFFFAOYSA-N 2-aminoethanol;1h-indole Chemical class NCCO.C1=CC=C2NC=CC2=C1 RUCHEPWOSATICL-UHFFFAOYSA-N 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 abstract 1
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 101710150192 Beta-secretase 1 Proteins 0.000 abstract 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE INDOL HIDROXIETILAMINA TRICICLICA E SEU USO NO TRATAMENTO DA DOENçA DE ALZHEIMER A presente invenção se refere a novos compostos de hidroxietilamina com atividade inibidora de Asp2 ( - secretase, bacei ou memapsina) de fórmula (I), a processos para sua preparação, a composições que os contenham e a seu uso no tratamento de doenças caracterizadas por níveis de - amilóide elevados ou depósitos de -amilóide, particularmente doença de alzheimer. Na fórmula (I), entre outros, A-B representa -NR5-SO2- ou -NR5 -CO-; R5 representa hidrogênio,C1-6 alquila, C3-6 alcenila C3-6 alcinila, C3-10 cicloalquila, -C0-6 ALQUILARILA, -C0-6 alquil-heteroarila, -C0-6 alquil-heterociclila, -C3-10 cicloalquilarila ou -C3-10 CICLOALQUIL-HETEROARILA; -W- REPRESENTA -CH2-, -(CH2)2-, -(CH2)3-, -C(H) =C (H)- ou -CH2-C(H)=C(H)-; X-Y-Z representa -C=CR8-NR9 - .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0328900.6A GB0328900D0 (en) | 2003-12-12 | 2003-12-12 | Novel compounds |
| PCT/EP2004/014076 WO2005058915A1 (en) | 2003-12-12 | 2004-12-09 | Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417476A true BRPI0417476A (pt) | 2007-05-08 |
Family
ID=30130158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417476-3A BRPI0417476A (pt) | 2003-12-12 | 2004-12-09 | derivados de indol hidroxietilamina tricìclica e seu uso no tratamento da doença de alzheimer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070073060A1 (pt) |
| EP (1) | EP1692143B1 (pt) |
| JP (1) | JP2007513913A (pt) |
| KR (1) | KR20060121164A (pt) |
| CN (1) | CN1914214A (pt) |
| AT (1) | ATE414090T1 (pt) |
| AU (1) | AU2004299231A1 (pt) |
| BR (1) | BRPI0417476A (pt) |
| CA (1) | CA2549072A1 (pt) |
| DE (1) | DE602004017777D1 (pt) |
| GB (1) | GB0328900D0 (pt) |
| IL (1) | IL175819A0 (pt) |
| IS (1) | IS8521A (pt) |
| MA (1) | MA28241A1 (pt) |
| NO (1) | NO20063137L (pt) |
| RU (1) | RU2006124863A (pt) |
| WO (1) | WO2005058915A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558034A1 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US7385085B2 (en) | 2004-07-09 | 2008-06-10 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| WO2006033000A2 (en) * | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-ethyl hydroxyethylamine useful in treating cns conditions |
| GB0422765D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| GB0422766D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7872009B2 (en) * | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| NZ582871A (en) * | 2007-07-27 | 2011-09-30 | Sanofi Aventis | 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| FR2919285B1 (fr) | 2007-07-27 | 2012-08-31 | Sanofi Aventis | Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919289B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919288B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique. |
| BRPI0913188A2 (pt) | 2008-05-29 | 2016-01-12 | Albany Molecular Res Inc | moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos |
| FR2960876B1 (fr) | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| US9045445B2 (en) | 2010-06-04 | 2015-06-02 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| JP6219955B2 (ja) * | 2012-08-24 | 2017-10-25 | トレヴェンティス コーポレイションＴｒｅｖｅｎｔｉｓ Ｃｏｒｐｏｒａｔｉｏｎ | ベンゾフラザン抗アミロイド化合物および方法 |
| US11214579B2 (en) * | 2017-10-13 | 2022-01-04 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
| US12043631B2 (en) | 2017-10-13 | 2024-07-23 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0958293B1 (en) * | 1997-02-04 | 2005-01-19 | The Regents Of The University Of California | Nanomolar, non-peptide inhibitors of cathepsin d |
| US6207664B1 (en) * | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
| JP2003528071A (ja) * | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| JP2004502665A (ja) * | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| RS50504A (sr) * | 2001-11-08 | 2007-04-10 | Elan Pharmaceuticals Inc., | Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana |
| GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-12-12 GB GBGB0328900.6A patent/GB0328900D0/en not_active Ceased
-
2004
- 2004-12-09 WO PCT/EP2004/014076 patent/WO2005058915A1/en not_active Ceased
- 2004-12-09 AU AU2004299231A patent/AU2004299231A1/en not_active Abandoned
- 2004-12-09 RU RU2006124863/04A patent/RU2006124863A/ru not_active Application Discontinuation
- 2004-12-09 CA CA002549072A patent/CA2549072A1/en not_active Abandoned
- 2004-12-09 CN CNA2004800416435A patent/CN1914214A/zh active Pending
- 2004-12-09 JP JP2006543488A patent/JP2007513913A/ja not_active Withdrawn
- 2004-12-09 US US10/596,296 patent/US20070073060A1/en not_active Abandoned
- 2004-12-09 AT AT04803724T patent/ATE414090T1/de not_active IP Right Cessation
- 2004-12-09 DE DE602004017777T patent/DE602004017777D1/de not_active Expired - Fee Related
- 2004-12-09 BR BRPI0417476-3A patent/BRPI0417476A/pt not_active IP Right Cessation
- 2004-12-09 EP EP04803724A patent/EP1692143B1/en not_active Expired - Lifetime
- 2004-12-09 KR KR1020067011376A patent/KR20060121164A/ko not_active Withdrawn
-
2006
- 2006-05-22 IL IL175819A patent/IL175819A0/en unknown
- 2006-06-26 MA MA29143A patent/MA28241A1/fr unknown
- 2006-06-26 IS IS8521A patent/IS8521A/xx unknown
- 2006-07-06 NO NO20063137A patent/NO20063137L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2549072A1 (en) | 2005-06-30 |
| GB0328900D0 (en) | 2004-01-14 |
| NO20063137L (no) | 2006-08-31 |
| US20070073060A1 (en) | 2007-03-29 |
| JP2007513913A (ja) | 2007-05-31 |
| EP1692143A1 (en) | 2006-08-23 |
| AU2004299231A1 (en) | 2005-06-30 |
| EP1692143B1 (en) | 2008-11-12 |
| ATE414090T1 (de) | 2008-11-15 |
| DE602004017777D1 (de) | 2008-12-24 |
| MA28241A1 (fr) | 2006-10-02 |
| KR20060121164A (ko) | 2006-11-28 |
| RU2006124863A (ru) | 2008-01-20 |
| IS8521A (is) | 2006-06-26 |
| WO2005058915A1 (en) | 2005-06-30 |
| IL175819A0 (en) | 2006-10-05 |
| CN1914214A (zh) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
| BRPI0409622A (pt) | derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer | |
| CY1111086T1 (el) | Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace) | |
| NO20063137L (no) | Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE602004014170D1 (de) | Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| WO2007019078A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
| HRP20060456A2 (hr) | Inhibitori 11-beta-hidroksisteroid-dehidrogenaze tipa 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |